Annual General Meeting of Shareholders in Basel, Switzerland

Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

ALLSCHWIL/BASEL, SWITZERLAND - 11 April 2008 - At today's Annual
General Meeting of Actelion Ltd (SWX: ATLN), shareholders approved
all resolutions.

Shareholders approved the annual report, including the financial
statements, for the year 2007 and confirmed Ernst & Young to serve as
the company's auditor for the year 2008.

The shareholders also re-elected Jean-Paul Clozel, Juhani Anttila and
Carl Feldbaum to serve for an additional three years on the Actelion
Board of Directors. The composition of the board, therefore, remains
unchanged. The eight members are: Robert E. Cawthorn (Chairman),
André J. Mueller (Vice-Chairman), Jean-Paul Clozel, Werner Henrich,
Armin Kessler, Jean Malo, Juhani Anttila and Carl Feldbaum.

The Annual General Meeting of Actelion took place in Basel. It was
attended by 225 shareholders, representing 48'620'320 shares or 39.56
percent of the total outstanding shares.

###
Actelion Ltd
Actelion Ltd is a biopharmaceutical company with its corporate
headquarters in Allschwil/Basel, Switzerland. Actelion's first drug
Tracleer®, an orally available dual endothelin receptor antagonist,
has been approved as a therapy for pulmonary arterial hypertension.
Actelion markets Tracleer® through its own subsidiaries in key
markets worldwide, including the United States (based in South San
Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in
innovative science related to the endothelium - the single layer of
cells separating every blood vessel from the blood stream. Actelion
focuses on the discovery, development and marketing of innovative
drugs for significant unmet medical needs. Actelion shares are traded
on the SWX Swiss Exchange (ticker symbol: ATLN).

For further information please contact:
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
Roland Haefeli
Vice President, Head of Investor Relations & Public
Affairs
+41 61 565 62 62
+1 650 624 69 36
http://www.actelion.com

--- End of Message ---

Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil
Switzerland

WKN: 936767; ISIN: CH0010532478; Index: SBIOM, SLIFE, SMCI, SMIEXP,
SMIM, SPI, SPIEX;
Listed: Main Market in SWX Swiss Exchange;